Pharmaceutical Manufacturing and Packaging of Morphine Sulfate Injection

The contract requires the manufacture, labeling, and packaging of Morphine Sulfate Injection at a concentration of 10mg/mL in 1x10 NEXJECT units, classified as a DEA Schedule II controlled substance, ensuring strict compliance with all applicable federal regulations including those set by the FDA, OSHA, and DLA. The product must adhere to precise quality, safety, and documentation standards appropriate for a high-risk controlled pharmaceutical, with packaging and labeling meeting all regulatory requirements for traceability, security, and handling. The work is to be performed at the designated place of performance in APO with ZIP code 09094-3219, under the oversight of the Department of Defense through the Medical Supply Chain Pharm FSA, and the solicitation is issued as a subcontract with a NAICS code of 325412 for pharmaceutical preparation manufacturing. Responses to this solicitation are due by August 4, 2026, with the opportunity published on July 29, 2026, indicating a limited bid window of one week. All proposals must demonstrate proven capability in handling DEA Schedule II substances, robust quality control systems, validated packaging processes, and full compliance with federal controlled substance handling protocols. The nature of the product and the federal context necessitate secure, auditable manufacturing practices with no tolerance for deviation from regulatory standards, and successful contractors must be equipped to meet the stringent demands of military medical supply chains while maintaining uninterrupted availability of this critical pain management medication.